Literature DB >> 3242583

Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

A M Evans1, R L Nation, L N Sansom, F Bochner, A A Somogyi.   

Abstract

1. Although it is well recognised that the enantiomers of a chiral drug may possess different pharmacokinetic and pharmacodynamic properties, many studies dealing with chiral drugs which are administered as their racemates rely on non-stereoselective analytical techniques. 2. We present a theoretical analysis to illustrate the potential which exists for misinterpretation of drug disposition and plasma drug concentration-effect data generated for a racemic drug using a non-stereoselective assay. 3. It was shown that the use of such an analytical method can lead to the collection of data which may be both quantitatively and qualitatively inaccurate with respect to the individual enantiomers. For example, the clearance of the unresolved drug may indicate concentration- and time-dependence even though this pharmacokinetic process is concentration- and time-independent for each of the enantiomers. 4. The problems discussed emphasise the need to consider stereoselectivity in clinical pharmacological studies involving racemic drugs.

Mesh:

Year:  1988        PMID: 3242583      PMCID: PMC1386594          DOI: 10.1111/j.1365-2125.1988.tb05318.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Bias in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns; E W Wuis
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

Review 2.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

3.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 4.  Serum tocainide enantiomer concentrations in human subjects.

Authors:  A J Sedman; J Gal; W Mastropaolo; P Johnson; J D Maloney; T P Moyer
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

5.  Pharmacokinetics of ibuprofen in man IV: absorption and disposition.

Authors:  J G Wagner; K S Albert; G J Szpunar; G F Lockwood
Journal:  J Pharmacokinet Biopharm       Date:  1984-08

6.  Effects of age on the clinical pharmacokinetics of ibuprofen.

Authors:  K S Albert; W R Gillespie; J G Wagner; A Pau; G F Lockwood
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

7.  Stereoselective pharmacokinetics of disopyramide enantiomers in man.

Authors:  J J Lima; H Boudoulas; B J Shields
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

8.  Stereoselective disposition of ibuprofen enantiomers in man.

Authors:  E J Lee; K Williams; R Day; G Graham; D Champion
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  The warfarin-sulfinpyrazone interaction: stereochemical considerations.

Authors:  S Toon; L K Low; M Gibaldi; W F Trager; R A O'Reilly; C H Motley; D A Goulart
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

10.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more
  14 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Chirality and drugs used to treat psychiatric disorders.

Authors:  Glen B Baker; Trevor I Prior; Ronald T Coutts
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 3.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 4.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Racemic therapeutics--ethical and regulatory aspects.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Stereoselectivity in pharmacokinetics: a general theory.

Authors:  R H Levy; A V Boddy
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

Review 7.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 8.  Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.

Authors:  E J Lee; K M Williams
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 9.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

10.  In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.

Authors:  F C Kugelberg; G Apelqvist; B Carlsson; J Ahlner; F Bengtsson
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.